BCL2 is a critical anti-apoptotic protein involved in resistance to DNA damaging agents in many cancer types [30], for which pharmacological inhibitors are available, some of which have shown promising results in the treatment of solid tumors [31, 32]. This evidence concerns the gene BCL2 and cancer.